- No file added yet -
Should sodium glucose co-transporter 2 inhibitors be considered as first line oral therapy for people with type 2 diabetes?
journal contribution
posted on 2018-09-27, 08:39 authored by Kamlesh Khunti, Samuel Seidu, Melanie J. DaviesType 2 diabetes mellitus (T2DM) is a chronic condition associated with long-term microvascular and macrovascular complications. Evidence-based guidelines recommend the individualisation of therapies to manage hyperglycaemia in order to reduce risk of complications.
Funding
This article is based on an invited oral symposium presentation at the Diabetes UK Professional Conference in London in March 2018. KK acknowledge the support from National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care – East Midlands (NIHR CLAHRC – EM) and the NIHR Leicester, Biomedical Research Centre.
History
Citation
Diabetes, Obesity and Metabolism, 2018Author affiliation
/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Diabetes Research CentreVersion
- AM (Accepted Manuscript)
Published in
DiabetesPublisher
Wileyissn
1462-8902eissn
1463-1326Acceptance date
2018-08-29Copyright date
2018Available date
2019-09-03Publisher DOI
Publisher version
https://onlinelibrary.wiley.com/doi/abs/10.1111/dom.13518Notes
The file associated with this record is under embargo until 12 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.Language
enAdministrator link
Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC